Linked Life Data

3652055

Source:http://linkedlifedata.com/resource/pubmed/id/3652055

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1987-11-12
pubmed:abstractText
Thirteen patients with transitional cell carcinoma of the bladder received monthly circadian-timed doxorubicin and cisplatin chemotherapy immediately after radical cystectomy. In five patients cancer had spread through the serosa of the bladder wall and/or into the perivesical fat (stage C). In eight patients cancer had spread to other pelvic tissues and pelvic lymph nodes (stage D1). Ten of these 13 patients showed no recurrence of disease after a median follow-up period of 3.5 years (range, 1 to greater than 5.5); these patients received no chemotherapy for a median duration of 3 years (range, 2-5). Two of the three patients who ultimately failed had local tumor recurrence which occurred much later than is the usual case (40 and 52 months). This circadian-timed two-drug regimen, given in full doses for nine courses as adjuvant treatment, delays and may prevent local and distant recurrence of stage C and D1 bladder cancer.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0361-5960
pubmed:author
pubmed:issnType
Print
pubmed:volume
71
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
915-9
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
High-dose intensity, circadian-timed doxorubicin and cisplatin adjuvant chemotherapy for bladder cancer.
pubmed:affiliation
Department of Medicine, University of Minnesota Medical School, Minneapolis.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't